Chlamydia is reported as the most prevalent among the different types of sexually transmitted disease. At present, fewer than 50% of sexually active young females in the United States are screened for the presence of chlamydiae. It has been analyzed that, if left untreated, it can become pelvic inflammatory disease (PID), which is a major cause of infertility, ectopic pregnancy and chronic pelvic pain. Considering this fact, several doctors are increasing their focus on treatment of sexually transmitted diseases worldwide, which as a result boosting the Chlamydia Infection market growth. A new study, covering the descriptive pharmacological action of the therapeutics, its complete research and development history has been published to the online repository of Market Research Hub (MRH) and titled as "Chlamydia Infections- Pipeline Review, H2 2017".